Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
270
resultados
Última actualización
01/05/2026 [09:01:00]
Resumen de: EP4733761A1
0001 A simple and rapid method is provided for screening proteins associated with neurodegenerative diseases or compounds useful for the treatment or prevention of neurodegenerative diseases. The method uses a probe comprising a polypeptide comprising a dipeptide repeat sequence consisting of repeating units selected from the group consisting of proline-arginine, glycine-arginine, proline-alanine, glycine-alanine, and glycine-proline, and an environment-sensitive fluorophore covalently linked thereto.
Resumen de: EP4733767A2
A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample.
Resumen de: EP4733313A2
0001 Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.
Resumen de: US20260109946A1
The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.
Resumen de: WO2024200757A1
The present disclosure relates to methods of identifying and reducing anti-Fc epsilon Receptor I (FcεRI) immunoglobulins (Ig) associated with adverse reactions from plasma or a fraction thereof, formulations and uses of the anti-FcεRI Ig reduced plasma protein product thereof.
Resumen de: US20260110682A1
0000 Methods for identifying agents or manipulations that modulate copper (Cu) dyshomeostasis in an Mblac1- or swip-10-dependent manner, and for identifying agents that support Cu-dependent neuronal health in a subject are provided.
Resumen de: US20260110699A1
0000 A method for detection or monitoring status of traumatic brain injury (TBI) and/or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP/FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP/FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.
Resumen de: US20260109740A1
The disclosure provides, in various embodiments, polynucleotides comprising a polyamine-responsive element and a reporter protein coding sequence encoding a reporter protein, wherein interaction between a polyamine and the polyamine-responsive element modulates expression of the reporter protein. The disclosure also provides, in various embodiments, vectors cells, and kits comprising the polynucleotides, methods of reporting an intracellular polyamine, and methods of detecting and/or reporting an intracellular polyamine analog.
Resumen de: WO2026084162A1
The present invention relates to a method for controlling the length of amyloid fibrils through a pressurized cutting process. Specifically, according to the present invention, long amyloid fibrils having a relatively long length can be uniformly cut into a desired specific length, and thus fibrils having a predetermined length can be produced precisely and reproducibly, thereby enabling cytotoxicity analysis according to the length of amyloid fibrils in neurodegenerative disease research. In addition, amyloid fibrils according to the present invention consistently maintain electrical properties, mechanical properties, and chemical reactivity due to the uniform and consistent length thereof, and thus may be suitable for commercial applications. In addition, since the pressurized cutting process of the present invention is relatively simple and economical, the commercial potential of various products and services using amyloid fibrils can be increased. Therefore, the pressurized cutting process is highly likely to be used in various technical fields such as neurodegenerative disease research, biosensors, filtration systems, nano-electronic devices, nanoparticles for drug screening, and bioadhesives.
Resumen de: WO2026084225A1
The present invention relates to a method for screening a lysophagy activator by promoting ubiquitination, and a pharmaceutical composition that contains the lysophagy activator selected by the screening method, and thus can treat or prevent lysosomal regulatory disorders, such as lysosomal storage disorders, neurodegenerative diseases, diabetes, or cancers.
Resumen de: WO2026084043A1
The present disclosure provides a technique relating to mild cognitive impairment detection using a skin blotting sample. In this disclosure, the mild cognitive impairment detection uses a mild cognitive impairment detection marker containing at least one selected from the group consisting of Aβ - (39 + 37 + 36)/ALB, Aβ - (39 + 37)/ALB, and Aβ - (37 + 36)/ALB as a detection index.
Resumen de: WO2026084453A1
The present invention relates to a drug delivery system capable of efficiently penetrating the blood-brain barrier (BBB). More specifically, the present invention relates to a drug delivery platform which fuses transthyretin (TTR) or a functional variant thereof with a peptide sequence comprising a certain amino acid sequence, and thus can be applied to a therapeutic agent for brain diseases and a diagnostic composition.
Resumen de: AU2024342922A1
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
Resumen de: US20260110685A1
Disclosed herein are methods for analyzing quantitative expression values of biomarkers of a biomarker panel for determining disease activity in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of predictive models for determining disease activity in human subjects based on the quantitative expression values of the markers.
Resumen de: US20260110700A1
Provided are methods and kits for blood sample collection, protein extraction, and analysis of neuro biomarkers obtained from blood samples on dried blood drop cards.
Resumen de: EP4729943A2
0001 Disclosed herein are improved methods of assessing Glial fibrillary acidic protein (GFAP) status in a subject (such as for examples, as a measure of traumatic brain injury or for other clinical reasons).
Resumen de: EP4729538A2
0001 The present invention relates to Tau-binding antibodies and binding fragments thereof.
Resumen de: EP4729947A2
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.
Resumen de: WO2023238955A1
The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found that an Aβ peptide, or a sweet amino acid or an umami substance specifically binds to a type I taste receptor on the surface of a nerve cell to exert an agonist-like or antagonist-like action, thereby amplifying or suppressing a VGSC active current. Moreover, with the binding of an Aβ peptide or the like to a type I taste receptor, the amplification of a VGSC active current occurs, the overactivity of nerve cells causing epileptiform attack occurs, and a large number of substances, which can effectively suppress the amplification of the VGSC active current, among ligand substances that specifically bind to the type I taste receptor, can be found. The present invention provides: a type I taste receptor-specific ligand substance that can control the amplification or suppression of a VGSC active current; and a pharmaceutical composition for preventing or treating various neurodegenerative diseases, such as Alzheimer's disease (AD), due to the amplification of a VGSC active current caused by the binding of an Aβ peptide or the like to a type I taste receptor. Moreover, a method for using, as a target receptor, a type I taste receptor present in a nerve cell or the like to screen a ligand substance for controlling a VGSC or the like in the ce
Resumen de: US20260102391A1
The present disclosure relates generally to methods of inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular organisms, to methods of identifying agents which inhibit such complex and to the medical use of those agents. Inhibition of the VOR complex causes interference with at least one mechanism of intercellular communication, wherein the intercellular communication is mediated by receptor-ligand interaction and/or EVs, and viral infection involving the transport of endocytosed biomaterials to the nucleus of recipient cells.
Resumen de: US20260103683A1
The disclosure relates to methods of generating at least one brain organoid-sufficient embryoid body or repairing at least one non-viable embryoid body, the method comprising incubating a population of induced pluripotent stem cells (iPSCs) in an embryoid body formation medium (EB FM), the EB FM comprising a culture medium, glutamine, recombinant human insulin, recombinant human transferrin, sodium selenite, and thermostable fibroblast growth factor 2 (FGF2). The disclosure further relates to methods of generating brain organoids from brain organoid-sufficient embryoid bodies and repairing embryoid bodies.
Resumen de: US20260103494A1
This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vector; and vectors or compositions for use in the treatment of AP-4-Hereditary Spastic Paraplegia.
Resumen de: US20260104419A1
Disclosed herein are methods for detecting or determining an amount, quantity, concentration and/or level of an anti-transcription factor A, mitochondrial (TFAM) antibody, such as an anti-human TFAM antibody, in one or more biologics samples obtained from a subject. In some aspects, the methods relate to identifying a subject suffering from systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome that is at risk of thrombosis, malignancy, death or any combination thereof.
Resumen de: WO2026080556A1
Methods for assessing the likelihood of delayed graft function (DGF) of a donor kidney in a kidney transplant recipient are provided. Additionally, methods for determining the likelihood of requiring dialysis in a kidney transplant recipient are provided. Such methods include measuring expression of at least one gene in a sample from the kidney for transplant or from the transplanted kidney.
Nº publicación: WO2026079284A1 16/04/2026
Solicitante:
EISAI R&D MAN CO LTD [JP]
\u30A8\u30FC\u30B6\u30A4\u30FB\u30A2\u30FC\u30EB\u30FB\u30A2\u30F3\u30C9\u30FB\u30C7\u30A3\u30FC\u30FB\u30DE\u30CD\u30B8\u30E1\u30F3\u30C8\u682A\u5F0F\u4F1A\u793E
Resumen de: WO2026079284A1
Disclosed is a method for quantifying DOPA decarboxylase in a biological sample. The method includes bringing the biological sample into contact with a first anti-DOPA decarboxylase antibody or an antigen-binding fragment thereof.
BOPI
Sede Electrónica
